MedTrace Logo

ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography

NCT06676280 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5000

Last updated 2026-01-29

No results posted yet for this study

Summary

The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcification (CAC ≥300).

Conditions

Interventions

DRUG

Aspirin

Patients will take aspirin 100 mg/day.

DRUG

High-intensity statin

Statin intensity is defined as 2018 Cholesterol Clinical Practice Guidelines.

DRUG

Guideline-directed statin therapy

as 2018 Cholesterol Clinical Practice Guidelines.

Sponsors & Collaborators

  • Jung-min Ahn

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-24
Primary Completion
2035-03-31
Completion
2035-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06676280 on ClinicalTrials.gov